Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Britain Courts Anthropic Amid US Defense Department Dispute 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
ATLANTA, Sept. 06, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016 earnings conference call and webcast while it concludes discussions involving the accounting treatment for its recent sale of its Inavir® royalty rights to HealthCare Royalty Partners. Aviragen will announce the new time for its conference call and webcast in the next several days.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
